COMMUNIQUÉS West-GlobeNewswire

Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza
23/09/2024
The Phase 2b trial will enroll 5,000 subjects across clinical sites in the US and UK SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary [...]
Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
23/09/2024
Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) Poster presentations of post-hoc [...]
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group Announce New Collaboration Agreement
23/09/2024
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group Announce New Collaboration Agreement Paris, France, September 23, 2024, 2:00 pm CET - The European Microbiome Innovation for Health [...]
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
22/09/2024
Webcast to be held Monday, September 23, at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 22, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey [...]
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
21/09/2024
As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia , including TEV -‘ 749 Currently, there is no long-acting olanzapine [...]
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
21/09/2024
As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia throu gh scientific and clinical advances that support optimal treatment options and decisions for [...]
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
21/09/2024
Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant Approval based on positive [...]
Communiqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagnostiqué (...)
21/09/2024
Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagnostiqué, non éligibles à une [...]
Smart for Life Provides Update Following Nasdaq Delisting Due to Audit Delays; Reports Plans to Reapply to Nasdaq Upon Full Compliance
20/09/2024
MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (OTC: SMFL) (“Smart for Life” or the “Company”), a distinguished leader in the Health & Wellness sector specializing in the marketing and manufacturing [...]
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20/09/2024
BRISBANE, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class 1 targeted and immune-mediated therapeutics to fight [...]
Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2024
20/09/2024
JI’AN, Jiangxi, China, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company,” “we,” “our” and “us”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced its [...]
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20/09/2024
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody-drug [...]
ONWARD® Medical Annonce la Cotation de ses Titres sur le Marché Euronext Paris
20/09/2024
La société a des racines françaises et des liens significatifs avec la France La société collabore étroitement avec le CEA-Clinatec, institut de recherche biomédicale de renommée mondiale financé par le gouvernement [...]
L’Arche Vancouver opens new $37-Million Dream Home
20/09/2024
BURNABY, British Columbia, Sept. 20, 2024 (GLOBE NEWSWIRE) -- L’Arche Greater Vancouver has fulfilled the biggest dream in its 50-year history today, by replacing its old building on the Sussex Avenue property in [...]
Wounded Warriors Family Support Provides Veterans with Program Toward Financial Competency, Independence
20/09/2024
OMAHA, Neb., Sept. 20, 2024 (GLOBE NEWSWIRE) -- According to a 2021 Military Family Support Programming Survey, 80.7% of respondents indicated that their finances caused them some stress over the past 12 months. The [...]
Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C
20/09/2024
MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), an ultra-rare and progressive neurodegenerative disease MIPLYFFA is indicated for use in combination with miglustat for the treatment [...]
TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.
20/09/2024
TAMPA, FL and COMMACK, NY, Sept. 20, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. (“TRxADE”) (NASDAQ: MEDS) and Scienture, LLC (“Scienture”), a wholly owned subsidiary of TRxADE, today announced that it is changing its [...]
Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders
20/09/2024
CINCINNATI, Ohio, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of [...]
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs
20/09/2024
PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being NEW YORK, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc (" Psyence Group " or the [...]

Pages